1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Fibromyalgia Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2030
1.2.2 Serotonin Norepinephrine Reuptake Inhibitors
1.2.3 GABA Analogs
1.2.4 Other
1.3 Market by Application
1.3.1 Global Fibromyalgia Drugs Market Share by Application: 2017 VS 2021 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Fibromyalgia Drugs Market Perspective (2017-2030)
2.2 Fibromyalgia Drugs Growth Trends by Region
2.2.1 Fibromyalgia Drugs Market Size by Region: 2017 VS 2021 VS 2030
2.2.2 Fibromyalgia Drugs Historic Market Size by Region (2017-2023)
2.2.3 Fibromyalgia Drugs Forecasted Market Size by Region (2023-2030)
2.3 Fibromyalgia Drugs Market Dynamics
2.3.1 Fibromyalgia Drugs Industry Trends
2.3.2 Fibromyalgia Drugs Market Drivers
2.3.3 Fibromyalgia Drugs Market Challenges
2.3.4 Fibromyalgia Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Fibromyalgia Drugs Players by Revenue
3.1.1 Global Top Fibromyalgia Drugs Players by Revenue (2017-2023)
3.1.2 Global Fibromyalgia Drugs Revenue Market Share by Players (2017-2023)
3.2 Global Fibromyalgia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Fibromyalgia Drugs Revenue
3.4 Global Fibromyalgia Drugs Market Concentration Ratio
3.4.1 Global Fibromyalgia Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fibromyalgia Drugs Revenue in 2021
3.5 Fibromyalgia Drugs Key Players Head office and Area Served
3.6 Key Players Fibromyalgia Drugs Product Solution and Service
3.7 Date of Enter into Fibromyalgia Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Fibromyalgia Drugs Breakdown Data by Type
4.1 Global Fibromyalgia Drugs Historic Market Size by Type (2017-2023)
4.2 Global Fibromyalgia Drugs Forecasted Market Size by Type (2023-2030)
5 Fibromyalgia Drugs Breakdown Data by Application
5.1 Global Fibromyalgia Drugs Historic Market Size by Application (2017-2023)
5.2 Global Fibromyalgia Drugs Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America Fibromyalgia Drugs Market Size (2017-2030)
6.2 North America Fibromyalgia Drugs Market Size by Country (2017-2023)
6.3 North America Fibromyalgia Drugs Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Fibromyalgia Drugs Market Size (2017-2030)
7.2 Europe Fibromyalgia Drugs Market Size by Country (2017-2023)
7.3 Europe Fibromyalgia Drugs Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Fibromyalgia Drugs Market Size (2017-2030)
8.2 Asia-Pacific Fibromyalgia Drugs Market Size by Country (2017-2023)
8.3 Asia-Pacific Fibromyalgia Drugs Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Fibromyalgia Drugs Market Size (2017-2030)
9.2 Latin America Fibromyalgia Drugs Market Size by Country (2017-2023)
9.3 Latin America Fibromyalgia Drugs Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Fibromyalgia Drugs Market Size (2017-2030)
10.2 Middle East & Africa Fibromyalgia Drugs Market Size by Country (2017-2023)
10.3 Middle East & Africa Fibromyalgia Drugs Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Fibromyalgia Drugs Introduction
11.1.4 Pfizer Revenue in Fibromyalgia Drugs Business (2017-2023)
11.1.5 Pfizer Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Detail
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Fibromyalgia Drugs Introduction
11.2.4 Eli Lilly Revenue in Fibromyalgia Drugs Business (2017-2023)
11.2.5 Eli Lilly Recent Development
11.3 Actavis
11.3.1 Actavis Company Detail
11.3.2 Actavis Business Overview
11.3.3 Actavis Fibromyalgia Drugs Introduction
11.3.4 Actavis Revenue in Fibromyalgia Drugs Business (2017-2023)
11.3.5 Actavis Recent Development
11.4 Merck Sharp and Dohme
11.4.1 Merck Sharp and Dohme Company Detail
11.4.2 Merck Sharp and Dohme Business Overview
11.4.3 Merck Sharp and Dohme Fibromyalgia Drugs Introduction
11.4.4 Merck Sharp and Dohme Revenue in Fibromyalgia Drugs Business (2017-2023)
11.4.5 Merck Sharp and Dohme Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Detail
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Fibromyalgia Drugs Introduction
11.5.4 Daiichi Sankyo Revenue in Fibromyalgia Drugs Business (2017-2023)
11.5.5 Daiichi Sankyo Recent Development
11.6 Innovative Med Concepts
11.6.1 Innovative Med Concepts Company Detail
11.6.2 Innovative Med Concepts Business Overview
11.6.3 Innovative Med Concepts Fibromyalgia Drugs Introduction
11.6.4 Innovative Med Concepts Revenue in Fibromyalgia Drugs Business (2017-2023)
11.6.5 Innovative Med Concepts Recent Development
11.7 Meda
11.7.1 Meda Company Detail
11.7.2 Meda Business Overview
11.7.3 Meda Fibromyalgia Drugs Introduction
11.7.4 Meda Revenue in Fibromyalgia Drugs Business (2017-2023)
11.7.5 Meda Recent Development
11.8 Meiji Seika
11.8.1 Meiji Seika Company Detail
11.8.2 Meiji Seika Business Overview
11.8.3 Meiji Seika Fibromyalgia Drugs Introduction
11.8.4 Meiji Seika Revenue in Fibromyalgia Drugs Business (2017-2023)
11.8.5 Meiji Seika Recent Development
11.9 Switch Biotech
11.9.1 Switch Biotech Company Detail
11.9.2 Switch Biotech Business Overview
11.9.3 Switch Biotech Fibromyalgia Drugs Introduction
11.9.4 Switch Biotech Revenue in Fibromyalgia Drugs Business (2017-2023)
11.9.5 Switch Biotech Recent Development
11.10 Theravance
11.10.1 Theravance Company Detail
11.10.2 Theravance Business Overview
11.10.3 Theravance Fibromyalgia Drugs Introduction
11.10.4 Theravance Revenue in Fibromyalgia Drugs Business (2017-2023)
11.10.5 Theravance Recent Development
11.11 Zynerba Pharmaceuticals
11.11.1 Zynerba Pharmaceuticals Company Detail
11.11.2 Zynerba Pharmaceuticals Business Overview
11.11.3 Zynerba Pharmaceuticals Fibromyalgia Drugs Introduction
11.11.4 Zynerba Pharmaceuticals Revenue in Fibromyalgia Drugs Business (2017-2023)
11.11.5 Zynerba Pharmaceuticals Recent Development
11.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
11.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Company Detail
11.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
11.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Drugs Introduction
11.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Drugs Business (2017-2023)
11.12.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
